Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients

E-ISSN： 2163-8306|4|6|362-371

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.6, 2015-06, pp. : 362-371

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis: An Evaluation Based on a 1-Year Randomised Controlled Trial

By Maetzel A.

PharmacoEconomics, Vol. 20, Iss. 1, 2002-01 ,pp. : 61-70

Adis International

Access to resources Recommend Favorite

Leflunomide for the treatment of rheumatoid arthritis

By Miceli-Richard Corinne Dougados Maxime

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Safety evaluation of leflunomide in rheumatoid arthritis

By I Keen Helen

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 581-588

Informa Healthcare

Access to resources Recommend Favorite

Leflunomide in Combination Therapy for Rheumatoid Arthritis

By Savage Ruth L.

Drug Safety, Vol. 33, Iss. 6, 2010-06 ,pp. : 523-526

Adis International

Access to resources Recommend Favorite

Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis

By Alldred A. Emery P.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 125-137

Informa Healthcare

Access to resources Recommend Favorite